DocumentsDate added
Review article
Uday Nandkishorji Soni1,*,Mayuresh J. Baheti1,Nandlal G. Toshniwal1¥
Affiliation:
1PG Student,1¥Professor and HOD, Department of Orthodontics and Dentofacial Orthopaedics, Rural Dental College, Pravara Institute of Medical Sciences, Loni – 413736,India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Orthodontics and Dentofacial Orthopaedics, Rural Dental College, Pravara Institute of Medical Sciences, Loni – 413736, India
Address reprint requests to
Dr. Uday Nandkishorji Soni.
Dept. of Orthodontics and Dentofacial Orthopaedics,
Rural Dental College, Pravara Institute of Medical Sciences, Loni–413736, India
Article citation: Soni UN,Baheti MJ,Toshniwal NG. Turmeric in dentistry – The hidden potential. J Pharm Biomed Sci.2015;05(01):84-89.Available at www.jpbms.info
ABSTRACT:
Turmeric has been used for thousands of years as a dye, a flavoring, and a medicinal herb. In India, it has been used traditionally as a remedy for stomach and liver ailments, as well as topically to heal sores. Ancient Indian medicine has touted turmeric as an herb with the ability to provide glow and luster to the skin as well as vigor and vitality to the entire body. The main component of turmeric is curcumin. The activity of curcumin derived from its complex chemistry as well as its ability to influence the multiple signalling pathways. Root part of the plant are widely used by different tribal communities as turmeric have been shown to have wide spectrum of biological actions, which include anti-inflammatory, anti-diabetic, analgesic, antibacterial, anti-fungal, anti-protozoal, anti-ulcer, hypocholesteremic activities. Its anti-cancer effect induced mainly mediated through induction of apoptosis and many more medicinal values.
This review article is to highlight the pharmacological action and its therapeutic role of turmeric in dentistry. This article is to illustrate the value of this medicinal spice and to emphasize to make an effective use of this in various dental applications.
KEYWORDS: Turmeric, Ayurveda, herbal medicine, Oral health.
Statement of Originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the
manuscript represents honest and original work.
REFERENCES
1.Roberson T, Harald OH, Edward JS. Sturdevant's Art and Science of Operative Dentistry. 10th ed. Elsevier Health Sciences,Australia, 2006.
2.World Health Organization - Global Strategy On Diet, Physical Activity And Health Facts: Dental Diseases And Oral Health .WHO oral health publications, Geneva 2003.
3.Balkland L, Ingle J, Baumgartner C. Ingles Endodontics . 6th edition.PMPH , USA . 2010. pp114.
4.Rapeephan Nagasiri, Chitmongkolsuk MS. Long-term survival of endodontically treated molars without crown coverage: A retrospective cohort study.JPD2003;93(2):164-170.
5.Bairwa M, Rajput M, Sachdeva S. Modified kuppuswamy's socioeconomic scale: social researcher should include updated income criteria, 2012. Indian J Community Med 2013; 38:185-6.
6.Satheesh BH, Omar S. Replacement of Missing Anterior Teeth in a Patient with Temporomandibular Disorder. Case Reports in Dentistry. 2014;39: 4.
Source of funding: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Copyright © 2015. Sisodia N,Yadav S,Nangia T,Singh P,Yadav M,Singh HP. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article
J.O. Sule1,*, F.M. Onyije2 and G.E. Onoru1
Affiliation:-
1Department of Biochemistry, Faculty of Basic Medical Sciences, College of Health Sciences, Niger Delta University, Wilberforce Island, Yenagoa, Bayelsa State, Nigeria
2Department of Medical Laboratory Science, Faculty of Basic Medical Sciences, College of Health Sciences, Niger Delta University, Wilberforce Island, Yenagoa, Bayelsa State, Nigeria.
The name of the department(s) and institution(s) to which the work should be attributed:
1.Department of Biochemistry, Faculty of Basic Medical Sciences, College of Health Sciences, Niger Delta University, Wilberforce Island, Yenagoa, Bayelsa State, Nigeria
2.Department of Medical Laboratory Science, Faculty of Basic Medical Sciences, College of Health Sciences, Niger Delta University, Wilberforce Island, Yenagoa, Bayelsa State, Nigeria.
Address reprint requests to
J.O Sule.
Department of Biochemistry, Faculty of Basic Medical Sciences, College of Health Sciences, Niger Delta University, Wilberforce Island,Yenagoa, Bayelsa State, Nigeria
Article citation:
Sule JO, Onyije FM, Onoru GE. The effects of Irvingia gabonensis (Bush mango) flesh and seed extracts on the biochemical and histological parameters of the liver in Wistar albino rats. J Pharm Biomed Sci.2015;05(01):25-30.Available at www.jpbms.info
ABSTRACT
Objective: To evaluate the biochemical and histological effects of Irvingia gabonensis (seeds and flesh) on the liver of male albino rats.
Materials and Methods: Twenty five male albino rats were divided into five groups (1-5), with five rats in each group in a completely randomized design. The treatment regime for the groups were; groups 1-2 received 0.8ml of normal saline, Group 3 received 200mg/Kgbw of I. gabonensis seed extract, Group 4 received 200mg/Kgbw of I. gabonensis flesh extract and Group 5 received 200mg/Kgbw of vitamin E. The treatment was administered once daily by oral intubation for 21 days. After which groups (2-5) received a single dose of 200mg/Kgbw acetaminophen.
Results: There is significant increase (p≤0.05) in the level of AST (44.73± 3.72) in untreated group when compared the treated groups (43.48±1.3 and 43.13± 5.02) for seed and flesh extracts respectively. ALT (18.60± 1.11) in seed extracts was not significantly different from the control (18.35 ± 1.34) but there was a significant decrease when compared with the standard group (19.08± 0.59). However, the flesh extract showed significant increase in the ALT (23.35± 3.88) when compared with the control. The levels of total protein decreased significantly in rat groups pretreated with seed extracts (54.80± 2.67) when compared with the negative control (58.87± 1.98). Also, level of total protein significantly increased (p≤0.05) in rat group pretreated with flesh extract when compared with the negative control. There is no significant difference in the levels of ALP in pretreated rat groups and the control. Photomicrographs of liver showed mild to severe degenerative effects on the histology of the liver investigated. Some of the histopathological effects observed in the liver were partial radial appearance from the Portal triad, total loss of radial appearance from the central vein, sinusoidal dilatation around the portal triad, congestion of portal triad with inflammatory cells, loss of radial appearance and distortion of tissue architecture.
Conclusion: This study provides evidence that I. gabonensis (seeds and flesh) consumption should be with caution.
KEYWORDS: I. gabonensis; Bush mango; Histology; Portal triad; Aminotransferase; BW (Body weight).
Source of support: None.
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
REFERENCES
1.Matos L, Nzikou JM, Matouba E, Pandzou-Yembe V N, Mapepoulou TG, Linder M, Desobry S. Studies of Irvingia gabonensisseeds kernels: Oil technological applications. Pak. J, Nutr. 2009 8: 151-157
2.Ngondi JL, Etoundi BC, Nyangono CB, Mbofung CMF, Oben JE.(http://creativecommons.org/licenses/by/2.0) 2009
3.Tchoundjeu Z, Atangana AR. Irvingia gabonensis (Aubry-LecomteexO’Rorke) Baill.Record from Protabase.van der Vossen HAM and Mkamilo G.S (editors). PROTA (Plant Resources of Tropical Africa / Ressources végétalesdel’ Afriquetropicale), Wageningen, The Netherland: http://database.prota.org/ search.htm. 2007
4.Nosiri I, Abdu-Aguye I, Hussaini MI, Abdurahaman E. Leaf Extracts Of Irvingia Gabonensis Increase Urine Output And Electrolytes In Rats. The Internet Journal of Alternative Medicine. 2011 ,8 : 2.
5.Ngondi JL, Oben JE, Minka SR. The effect of Irvingia gabonensis seeds on body weight and blood lipids of obese subjects in Cameroon. Lipids in health and Disease 2005; 4, 12-15.
6.Fajimi O, Sarumi MB, Olayode MN, Gamra EO, Sanusi SI. In vitro propagation of Irvingia gabonensis. African journal of biotechnology, 2007; 6(8): 976-978.
7.Bergemeyer HU, Bent E. Glutamate-oxaloacetate transaminase, glutamate pyruvate transaminase. In: Methods of Enzymatic Analysis (Bergmeyer HU, ed.), Academic Press, New York, 1963; 837–852.
8.Garen A, Levinthal C. A fine-structure genetic and chemical study of the enzyme alkaline phosphatase from E. coli. Purification and characterization of alkaline phosphatase. Biochim Biophys Acta, 1960; 38, 470–483.
9.Baker JF, Silverton ER. Kishaw D. Introduction to Medical Laboratory Technology, Butter worths, London, 1985; 316-369.
10.Smith GS, Nadig DE, Kokoska ER, Solomon H, Tiniakos DG, Miller TA. Role of neutrophils in hepatotoxicity induced by oral acetaminophen administration in rats. J. Surg. Res, 1998; 80, 252-258.
11.Edwards, CRW, Bouchier IAD, Haslet C, Chilvers ER. Davidson’s Principlesand practice of Medicine, 17th edn. Churchill Livingstone, 1995; 488 – 490.
12.Abatan MO, Arowolo ROA, Olorunsogo O. Pathological Effects of Lantana camara and Dichapet alummada gascasiense in Goats. Trop. Vet. Med, 1996; 14, 127 – 132.
13.Ojiakor OA, Nwanjo HU. Is Vernonia amygdalina hepatotoxic or hepatoprotective? Answers from biochemical and toxiclogical studies in rats. Afr. J. Biotechnol, 2006; 5(18), 1648-1651.
14.Ojekale AB, Ojiakor O A, Saibu GM, Lala A, Olodude OA. Long term effects of aqueous stem bark extract of Cissuspopulnea (Guill. and Per.) on some biochemical parameters in normal rabbits. Afr. J. Biotechnol., 2007; 6(3), 247-251.
15.Lambert JD, Sang S, Yang CS. Possible controversy over dietary polyphenols: Benefits vs risks. Chem. Res. Toxicol, 2007; 20(4), 583-585.
16.Adeline YL, Ignacio LS, Srikumar C, Sufyan A, Judson JP. Histopathology and biochemistry analysis of the interaction between sunitinib and paracetamol in mice.BMC Pharmacology , 2010; 10:14
17.Rivera L, Moron R, Sánchez M, Zarzuelo A, Galisteo M. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity 2008 ;16: 2081-7
18.Mukai K. Synthesis and Kinetic Study of Antioxidant and Prooxidant Actions of Vitamin E Derivates. In: Packer, L. and J. Fuchs, (Eds.), Vitamin E in Health and Disease. Marcel Dekker New York, 1993: 97-119.
19.Thomas SR, Neuzil J, Stocker R. Cosupplementation with coenzyme Q prevents the prooxidant effect of α-tocopherol and increases the resistance of LDL to transition metal-dependent oxidation initiation. Arterioscler.Thromb.Vasc.Biol, 1996; 16, 687-696. 20.Eder K, Flader D, Hirche F, Brandsch C. Nutrient interactions and toxicity: Excess dietary vitamin E lowers the activities of antioxidative enzymes in erythrocytes of rats fed salmon oil. J. Nutr.,2002; 132: 3400-3404.
21.Ladipo DO, Foundun JM, GanagaN. Domestication of bush mango (irvingiagabonensis): some exploitable intraspecific variations in west and central Africa. Food and agriculture organization, Rome. Italy. 1996
22.Ainge L, Brown N. Irvingia gabonensis and Irvingia wombolu.A State of Knowledge Report undertaken for The Central African Regional Program for the Environment. Oxford Forestry Institute. Department of Plant Sciences.University of Oxford. United Kingdom. 2001
23.Albert A. Irvingiagabonensis(African/Bush mango).Global Institute for BioExploration – Gibex. 2010
24.Rosen HR, Keefe EB. Evaluation of abnormal liver enzymes, use of liver tests and the serology of viral hepatitis: Liverdisease, diagnosis and management. 1st Ed. New York; Churchill livingstone publishers, 2000; 24-35.
Copyright © 2014 Sule JO, Onyije FM, Onoru GE. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Research article
Alyaa Hussein Hammadi1,*, Ali Abd-Alamer Jwad2, Ibrahim Adham Majeed3, Ehab Mudher Mikhael3
Affiliation:-
1Al-Diwaniya Teaching Hospital, Alqadisya, Iraq
2Lecturer of Otolaryngology, Department of General of Surgery, College of Medicine, University of AIqadisa, Al-Diwaniya, Iraq
3Clinical Pharmacy Department-College of Pharmacy- Baghdad University, Baghdad, Iraq
The name of the department(s) and institution(s) to which the work should be attributed:
Department of General of Surgery, College of Medicine, University of AIqadisa, Al-Diwaniya, Iraq
Author’s contributions:
Author 1 contributed towards concepts, design, literature survey, data acquisition, manuscript editing and preparation. Author 2& 3 contributed in Design, literature search and data acquisition.
Address reprint requests to
Alyaa H. Hammmdi.
Al-Diwaniya Teaching Hospital, Al-Diwaniya, Iraq
Article citation:
Hammmdi AH,Jwad AA,Majeed IA,Mikhae EM. The effectiveness, safety and cost of different intranasal steroid sprays in treating Iraqi patients with allergic rhinitis: A comparative study. J Pharm Biomed Sci.2015;05(01):61-66.Available at www.jpbms.info
ABSTRACT
Background: Allergic rhinitis is a common disease that associated with inflammation of the nasal airways resulting in symptoms of sneezing, nasal obstruction, and mucous discharge. Intranasal steroids are the first option for treatment of patients with mild – moderate AR. At which all available intranasal corticosteroids are safe and effective for this indication, differences in efficacy, side effects, and clinical attributes must be considered. So this study aimed to assess and compare the efficacy, safety and cost of different intranasal steroids (beclomethasone dipropinate, budesonide and mometasone furoate monohydrate) that available in Iraqi pharmacies for the treatment of allergic rhinitis patients.
Subjects & Methods: A randomized single blind clinical trial was done in Al-Diwaniya Teaching Hospital at ENT Unit at which sixty patients of both sexes with allergic rhinitis for at least 1 year were included in this study. The patients were divided into three groups with 20 patients in each group to receive either Beclomethasone dipropionate or mometasone furoate or Budesonide intranasal spray daily for 1 month. Clinical assessment of the allergic rhinitis is done by measuring symptom through the use of visual analog scales at beginning and at the end of the study. Blood samples of AR patients were collected at the beginning and at the end of the study to measure serum Immunoglublin E (IGE), Interleukin 5(IL5), Eocinophil cationic protein (ECP), Mast cell tryptase (MCT), T-Lymphocyte count.
Results: This study showed a non significant difference among intranasal steroids by their effect on lymphocyte count, IL5, MCT and ECP; however there was a significant difference in the effect of intranasal steroids on VAS, and IGE, at which VAS was significantly reduced by Beclomethasone; while IGE was significantly reduced by mometasone. Additionally there is a non significant difference in the topical side effects among all topical intranasal steroids. Furthermore there is a significantly higher monthly cost for the treatment of allergic rhinitis patients with mometasone nasal spray.
Conclusion: Beclomethasone dipropionate intranasal spray is an effective and cheap therapy when used for short periods for young adult allergic rhinitis patients without any risk from systemic side effects of steroids; while budesonide is a best alternative cheap therapy for Beclomethasone in allergic rhinitis with risk from systemic steroid side effects or who have compliance problems in using nasal steroids twice daily.
KEYWORDS: Allergic rhinitis; intranasal steroids; effectiveness, safety; cost.
REFERENCES
1.Passali D, Bellussi L, Damiani V, etal. Allergic rhinitis in Italy: epidemiology and definition of most commonly used diagnostic and therapeutic modalities. Acta Otorhinolaryngol Ital. 2003 Aug;23(4):257-64.
2.Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA). Allergy .2008; 63 (suppl 86):8–160.
3.Herman H. Once-daily administration of intranasal corticosteroids for allergic rhinitis: a comparative review of efficacy, safety, patient preference, and cost. Am J Rhinol. 2007;21:70–9.
4.Sur DK, Scandale S. Treatment of Allergic Rhinitis. Am Fam Physician. 2010 Jun 15; 81(12):1440-1446.
5.Wallace DV, Dykewics MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122(2 suppl):S1–S84.
6.Lee BJ, Kim YJ , Kim JH, Shin HS, Chung YS. A comparative study of intranasal budesonide and oral terfenadine in perennial allergic rhinitics: effect on the symptom score and nasal secretion eosinophils. J Asthma Allergy Clin Immunol. 2001; 21:216-22.
7.Stempel D. Improving the value of care for allergic rhinitis. Drug Benefit Trends. 1996; 8(1):11-2.
8.Mygind N, Lund V. Topical corticosteroid therapy of rhinitis. Clin Immunother .1996;5:122-36.
9.Lumry WR. A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis. J Allergy Clin Immunol. 1999;105:150-8.
10.Wallace DV, Dykewicz MS, Bernstein DI; Joint Task Force on Practice; American Academy of Allergy, Asthma & Immunology; American College of Allergy, Asthma & Immunology; Joint Council of Allergy, Asthma & Immunology. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122(2 suppl):S1-S84.
11.Erin EM, Leaker BR, Zacharasiewicz AS, etal. Single dose topical corticosteroid inhibits IL-5 and IL-13 in nasal lavage following grass pollen challenge. Allergy. 2005 Dec;60(12):1524-9.
12.Fokkens WJ, Rinia B, van Drunen CM, etal. No mucosal atrophy and reduced inflammatory cells: active-controlled trial with yearlong fluticasone furoatenasal spray. Am J Rhinol Allergy. 2012 Jan-Feb;26(1):36-44. doi: 10.2500/ajra.2012.26.3675.
13.Nielsen LP, Bjerke T, Christensen MB, Skamling M, etal. Eosinophil markers in seasonal allergic rhinitis. Intranasal fluticasone propionate inhibits local and systemic increases during the pollen season. Allergy. 1998 Aug ; 53(8):778-85.
14.Di Lorenzo G, Pacor ML, Pellitteri ME, Morici G, etal. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in monotherapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy. 2004 Feb;34(2):259-67.
15.G. K. Scadding, S. R. Durham, R. Mirakian, etal. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy. 2008 Jan;38(1):19-42.
16.Bryan Wong. A REVIEW OF INTRANASAL CORTICOSTEROIDS IN THE TREATMENT OF ALLERGIC RHINITIS. Pharmanote 2013; 28(10).
17.Corren J. Intranasal corticosteroids for allergic rhinitis: how do different agents compare? J Allergy Clin Immunol. 1999;2 :S144–S149. doi: 10.1016/S0091-6749(99)70310-6.
18.Peter Small, and Harold Kim. Allergic rhinitis: review. Allergy, Asthma & Clinical Immunology. 2011, 7(Suppl 1):S3.
19.J Sastre, R Mosges. Local and Systemic Safety of Intranasal Corticosteroids. J Investig Allergol Clin Immunol. 2012; 22(1): 1-12.
20.Lynn Lambert. Intranasal corticosteroids.S Afr Pharm J 2013; 80(6):22-24.
21.Waddell AN , Patel SK, Toma AG, Maw AR. Intranasal steroid sprays in the treatment of rhinitis: is one better than another? J Laryngol Otol. 2003;117(11):843-5.
Copyright © 2015. Hammmdi AH,Jwad AA,Majeed IA,Mikhae EM. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Case report
Cláudio Gleidiston Lima da Silva, Raul Rodrigues Barros, Bernardo Nogueira Faé, Jucier Gonçalves Júnior, João Vitor Cândido Pimentel, Modesto Leite Rolim Neto, Maria do Socorro Vieira dos Santos*
Affiliation:-
Faculty of Medicine,Federal University of Cariri, UFCA, Barbalha, Ceará, Brazil.
The name of the department(s) and institution(s) to which the work should be attributed:
Faculty of Medicine,Federal University of Cariri, UFCA, Barbalha, Ceará, Brazil.
Address reprint requests to
Maria do Socorro Vieira dos Santos.
284, Divine Savior Street, Downtown, Barbalha, Ceará, Brazil, 63180000.
Phone Number: +055(88)98214066
ABSTRACT:
Background: Strongyloidiasis is a parasitic infection caused most commonly by Strongyloides stercoralis, an endemic helminth in rural populations of tropical and subtropical climates. There are many clinical presentations, but most infected patient presents asymptomatically or with classic symptoms of helminthiasis; however, atypical presentations are occasionally seen. Case report: We report a case of strongyloidiasis simulating a gastric tumor, in a dyspeptic patient with risk factors for stomach cancer. Diagnosis was achieved through histopathology examination of the lesions, which showed larvae of S. stercoralis. This case was treated by Albendazole. Conclusions: After all, we concluded that gastrointestinal cancers must have strongyloidiasis as a differential diagnosis. And our case is important for (re-)estimating the burden of helminth infections and highlights the need for integrating epidemiological surveys, rigorous diagnostic approaches and clinical assessments in the developing world.
KEYWORDS: Atypical presentation; Case report; Strongyloidiasis.
Article citation:
Lima da Silva CG, Rodrigues RB, Faé BN, Gonçalve J, Pimentel Cândido JV, Rolim-Neto ML, et al. Strongyloidis stercoralis simulating gastric tumor: A case report. J Pharm Biomed Sci. 2014;05(01):06-09. Available at www.jpbms.info
REFERENCES
1.Naves, M.M., Costa-Cruz, J.M. High Prevalence of Strongyloides stercoralis infection among the elderly in Brazil. Rev. Inst. Med.Trop 2013; 55(5):309-313.
2.Khieu, V., Schär, F., Marti, H., Sayasone S., Duong S., Muth S. et al. Diagnosis, Treatment and Risk Factors of Strongyloides stercoralis in Schoolchildren in Cambodia. PLoS Negl Trop Dis 2013; 7(2): e2035.
3.Walker, S.L., Mann, T.A.N. Strongyloidiasis complicating immunosuppression for pemphigus vulgaris. Brit J Dermatol. 2013; 169(6): 1363-1364.
4.Repetto, A.S., Durán, P.A., Lasala, M.B., González-Cappa, S.M. High Rate of Strongyloidosis Infection Out of Endemic Area in Patients with Eosinophilia and without Risk of Exogenous Reinfections. Am. J. Trop. Med. Hyg. 2010; 82 (6): 1088-1093.
5.Rosso, D., Rigueiro, M.P., Kassab, P., Ilias, E.J., Castro, O.A.P., Novo, N.F. et al. Gástrico correlation of Natural Killer cell with the prognosis of gastric adenocarcinoma. ABCD, arq. bras. cir. dig. 2012; 25(2): 114-117
6.Bresciani, C., Ibrahim, L. I., Coser, R.B., Yagi, O., Deutsch, C.R., Mucerino, D. et al. Histopathological determination of Helicobacter pylori in gastric cancer. ABCD arq bras cir dig 2011;24(1): 59-63.
7.Ruy, J.C., Rodrigo, V., Bernardo, M.K. Duodenal obstruction - an unusual presentation of Strongyloides stercoralis enteritis: a case report. World J Emerg Surg. 2010; 5: 23.
8.Luna, O.B., Grasselli, R., Ananias, M., Pinto, T.S., Fernando, A.B., Soares, M. et al. Disseminated Strongyloidiasis: Diagnosis and Treatment. Rev Bras Ter Intensiva 2007; 19(4):463-8.
9.Saugar, J.M., Merino, F.J., Martín-Rabadán, P., Soto, P.F., Ortega, S., Gárate, T., Rodríguez, E. Application of real-time PCR for the detection of Strongyloides spp. in clinical samples in a reference center in Spain. Acta Trop 2014; 142: 20-25.
10.Mejia, R., Nutman, T.B. Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis. Curr Opin Infect Dis. 2012; 25(4): 458-63.
11.Werneck-Silva, A.L., Prado, I.B. Role of upper endoscopy in diagnosing opportunistic infections in human immunodeficiency virus-infected patients; World J Gastroenterol. 2009; 15(9): 1050–1056.
12.Meine, G.C., Dietz, J., Rocha, M., Mattos, T., Souza, A.R., Conteletti, F.R. Atypical gastric presentation of strongyloidiasis in HIV-infected patient--case report. Dig Liver Dis. 2004;36:760–762.
13.Thompson, B.F., Fry, L.C., Wells, C.D., Olmos, M., Lee, D.H., Lazenby, A.J. et al. The spectrum of GI strongyloidiasis: an endoscopic-pathologic study. Gastrointest Endosc. 2004;59:906–910.
14.Wu, T.C., Lei, W.Y., Chen, M.C., Hu, C.T. Strongyloides stercoralis infection: a health issue regarding indigenous people in Taiwan. Trans R Soc Trop Med Hyg 2012;106 (2012) 468–472.
15.Thaden, J., Cassar, A., Vaa, B., Phillips, S., Burkhart, H., Aubry, M. et al. Eosinophilic Endocarditis and Strongyloides stercoralis. Am J Cardiol. 2013;112(3):461-2.
16.Sykes, AM., McCarthy, J.S. A Coproantigen Diagnostic Test for Strongyloides Infection. PLoS Negl Trop Dis 2011; 5(2):e955.
17.Becker, S.L., Sieto, B., Silué, K.D., Adjossan, L., Koné, S., Hatz, C., et al. Diagnosis, Clinical Features and Self-Reported Morbidity of and Hookworm Infection in a Co-Endemic Setting. PLoS Negl Trop Dis 2011;5(8): e1292.
18.Anderson, N.W., Klein, D.M., Dornik, S.M., Jespersen, D.J., Kubofcik, J., Nutman, T.B. et al. Comparison of Three Immunoassays for Detection of Antibodies to Strongyloides stercoralis. Clin Vaccine Immunol 2014; 21 (5):732-6.
19.Bisoffi, Z., Buonfrate, D., Sequi, M., Mejia, R., Cimino, R.O., Krolewiecki, A.J. et al. Diagnostic Accuracy of Five Serologic Tests for Strongyloides. PLoS Negl Trop Dis. 2014; 8(1): e2640.
20.Salvador, F., Sulleiro, E., Sánchez-Montalvá, A., Saugar, J.M., Rodríguez, E., Pahiss, A. et al. Usefulness of Strongyloides stercoralis Serology in the Management of Patients with Eosinophilia. Am. J. Trop. Med. Hyg. 2014; 90(5): 830-834
21.Suputtamongkol, Y., Premasathian, N., Bhumimuang, K., Waywa, D., Nilganuwong, S., Karuphong, E. et al. Efficacy and Safety of Single and Double Doses of Ivermectin versus 7-Day High Dose Albendazole for Chronic Strongyloidiasis. PLoS Negl Trop Dis. 2011; 5(5): e1044.
22. Donadello, K., Cristallini, S., Taccone, F. S., Lorent, S., Vincent, J-L., Backer, D., et al. Strongyloides disseminated infection successfully treated with parenteral ivermectin: case report with drug concentration measurements and review of the literature. Int J Antimicrob Agents 2013; 42(6):580-3.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © 2014. Lima da Silva CG,Rodrigues RB,Faé BN,Gonçalve J,Pimentel Cândido JV,Rolim-Neto ML, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article
Purvi R Bhagat.1,*,M.S., D.O, Mariam N Mansuri2.,M.S.,Vibha Metha3.,M.S.
Affiliation:-
1Associate Professor,2Professor,3Senior Resident, Glaucoma Clinic, M & J Western Regional Institute of Ophthalmology, Ahmedabad-380016,Gujarat,India
The name of the department(s) and institution(s) to which the work should be attributed:
M & J Institute Of Ophthalmology, Civil hospital, Ahmedabad-380016,India
Address reprint requests to
Dr Bhagat Purvi R.
Associate Professor, Glaucoma Clinic, M & J Western Regional Institute of Ophthalmology,Ahmedabad- 380016, Gujarat, India or at dr.purvibhagat@yahoo.com
Article citation:
Bhagat PR,Mansuri MN,Mehta V. Primary congenital glaucoma The iceberg disease : Four years data from a tertiary care centre of a developing country. J Pharm Biomed Sci.2015;05(01):67-71. Available at www.jpbms.info
ABSTRACT
Context: Primary congenital glaucoma ( PCG ) is an uncommon type of glaucoma but due to the long anticipated life span of the afflicted, it leads to considerable economic blindness. Therefore, the importance of treating them young cannot be over emphasized.
Aim: The purpose of this study was to determine the total burden and epidemiology of PCG at a tertiary referral care centre.
Material & Methods: This was a retrospective study from January 2010 to December 2013 and included one fifty(150) eyes of 110 patients, aged < 11 years. Each patient underwent detailed systemic and ophthalmic examination, examination under anaesthesia (EUA) followed by appropriate surgical intervention.
Results: 68 (61.82%) patients were boys and 42 (38.18%) patients were girls. 41 (37.27%) patients belonged to 0-1 year age group; 29 (26.36%) patients to 1-5 years; 24 (21.82%) patients to 5-8 years and 16(14.54%) to 8-11 years. 70 (63.63%) patients had unilateral involvement, while 40 (36.36%) patients had bilateral affection. Nine(9) eyes required resurgery. Two(2) eyes of a single patient required resurgery twice. One(1) eye underwent shunt surgery.
Conclusion: Over the four year analysis, 150 eyes were found to be affected with PCG. Though this represents only the burden at a tertiary centre, this treatable and preventable cause of blindness raises an important field of concern. Concentrated efforts for early diagnosis and timely treatment can help to nullify the deleterious effects of PCG. Public education and active parental counselling are also additional keys for PCG prevention.
KEYWORDS: Glaucoma; Primary congenital glaucoma; Buphthalmos; Trabeculotomy.
Key message: Congenital glaucoma has an exorbitant impact on the lives of the afflicted, their families and on the productivity of the society but it still lacks attention. Over a four year retrospective analysis, 150 eyes were found to be affected with Primary congenital glaucoma. Though this number appears to be small and represents only the burden at a tertiary centre, this treatable and preventable cause of blindness raises an important field of concern if the results can be expanded to the community level. Concentrated efforts for early diagnosis and timely treatment can help to nullify the deleterious effects of PCG thereby improving the quality of the childs future. Public awareness and education remain the key. Discouraging consanguinous marriages and active parental counselling are also additional keys for PCG prevention.
Statement of Originality of work : The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
REFERENCES
1.Kingman S. Glaucoma is second leading cause of blindness globally. Bull World Health Organ 2004; 82(11): 811‐890.
2.Nduaguba C, Lee R. Glaucoma screening: current trends, economic issues, technology, and challenges. Curr Opin Ophthalmol 2006; 17: 142‐152.
3.Gupta N, Yülel YH. Glaucoma as a neurodegenerative disease. Curr Opin Ophthalmol 2007; 18: 110‐114.
4.Kyari F, Gudlavaletti MV, Sivsubramaniam S, Gilbert CE, Abdull MM, Entekume G, et al. Prevalence of blindness and visual impairment in Nigeria. Invest Ophthalmol Vis Sci 2009; 50: 2033-2039.
5.Dandona L, Williams JD, Williams BC. Population based assessment of childhood blindness in southern India. Arch Ophthalmol 1998; 116(4) : 545-46.
6.Papadopoulos M, Cable N, Rahi J, Khaw PT. British Infantile Glaucoma ( BIG ) study investigators. Invest Ophthalmo Vis Sci 2007; 48(9): 4100-06.
7.Panicker SG, Mandal AK, Reddy AB. Correlations of genotype with phenotype in Indian patients with primary congenital glaucoma. Invest Ophthalmol Vis Sci 2004; 45: 1149-56.
8.Yadava Usha. Primary congenital glaucoma. Journal of Current Glaucoma Practice 2010; 4(2) : 57-71.
9. Derrick S Fung, M Allison Roensch, Karanjit S Kooner, H Dwight Cavanagh, Jess T Whitson. Epidemiology and characteristics of childhood glaucoma: results from the Dallas Glaucoma Registry. Clinical Ophthalmology 2013; 7: 17391746
10.Das J, Bhomaj S, Chaudhuri Z, Sharma P, Negi A, Dasgupta A. Profile of glaucoma in a major eye hospital in North India. Indian J Ophthalmol 2001;49:25-30
11.Mandal AK, Chakrabarti D. Update on congenital glaucoma. Indian J Ophthalmol 2011; 59:148-57.
12.Tuck MW. Referrals for suspected glaucoma. An International Glaucoma Association. Survey Ophthalmol Physiol Opt 1991;11:22-26.
Copyright © 2015. Bhagat PR,Mansuri MN,Mehta V. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.